Kineta, Inc. and potential partner TuHura Biosciences revealed on 19 August that enrollment is resuming in the Phase I portion of a Phase I/II study of the anti-VISTA antibody KVA12123 in advanced solid tumors. The companies hope to establish a new class of immune checkpoint inhibitors and to succeed with a target where previous development efforts have been deterred by incidences of cytokine release syndrome (CRS).
Kineta Resumes Enrollment Of Anti-VISTA Antibody Trial
An option fee from potential program acquirer TuHura has enabled Kineta to resume enrolling a Phase I/II study of a VISTA-targeted antibody that the company thinks has best-in-class potential.
